We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Urine Test Diagnoses Bladder Cancer Early

By LabMedica International staff writers
Posted on 03 Jul 2014
A highly-specialized urine test can detect bladder cancer as much as three to six months earlier than an invasive cystoscopy procedure and can help physicians diagnose the disease at an initial stage, when treatment might be more effective. More...


The simple test requires a urine sample and involves the mapping of genetic material in human cells, including specific genes, in the laboratory and fluorescent dyes used in the test can detect genetic abnormalities linked to cancer.

Clinical scientists at Skyline Urology (Torrance, CA, USA) are urging individuals at risk for bladder cancer to undergo the urinary fluorescence in situ hybridization (FISH) test. The primary indicator or symptom of bladder cancer is blood in the urine, which is often detected first on a routine urine analysis test and may not be seen by the naked eye.

Caucasians are about twice as likely to develop bladder cancer as African Americans, and the risk of bladder cancer increases with age. About 9 out of 10 people with bladder cancer are over the age of 55. Bladder cancer is more common in men than in women, and chronic bladder irritation and urinary infections have been linked to bladder cancer.

Cystoscopy is commonly used to diagnose or rule out bladder cancer. In this procedure, the urologist will place a small fiber-optic cystoscope through the opening of the urethra and into the bladder so that the doctor may see the bladder lining. If an abnormal area or growth is seen, it will be biopsied. Cystoscopy can be performed in a doctor's office or in the operating room. A local anesthesia may be used to numb the urethra for the procedure. If a general or spinal anesthesia is used, the procedure is done in the operating room.

Alec S Koo, MD, FACS, a urologist at Skyline Urology, said, “The FISH test uses the latest molecular biology technology and is the first DNA testing used to detect cancer with only a sample of urine. The cost for such testing is higher than standard urine tests because of the sophisticated technology involved. However, when compared to other tests used to diagnose urinary cancer, such as computerized tomography (CT) scan or cystoscopy with anesthesia, the cost of FISH testing is comparable or lower, especially considering the possibility of lost work time following anesthesia.”

Related Links:

Skyline Urology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Urine Analyzer
respons® UDS100
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.